Pharma distribution runs on digital — but its three giants are still hard to see on the open web

Unlike most verticals we cover, pharma distribution isn’t adopting ecommerce — it runs on it. Ordering largely flows through customer systems and login-gated portals, and the Big Three keep modernizing that layer. At its June 2025 investor day, Cardinal said its Vantus HQ ordering platform for retail pharmacy customers — product search, order tracking, and analytics-driven reporting in one interface — had reached critical mass. McKesson, for its part, describes using machine-learning models to forecast medication demand and flag at-risk items. The story here is digital maturity, not digital adoption.

Here’s the twist that matters as AI agents start doing product discovery. Anglera’s Digital Readiness Index measures signals from public storefronts. In its 2026 pharma and healthcare ranking, McKesson, Cencora, and Cardinal Health had no published score; only one company in the vertical earned one, and it ranks seventh by revenue. The distinction matters: Anglera records McKesson as having no public catalog, while Cencora and Cardinal had a catalog found but not yet measured under the index’s rules. A channel this digital internally can still be difficult for the open web — and for buying agents — to see. That is a real strategic question if procurement starts flowing through AI.

The structure amplifies the stakes. McKesson, Cencora, and Cardinal Health account for more than 90% of U.S. wholesale drug distribution, and have spent more than $16 billion acquiring physician-practice management organizations in specialty and oncology channels. The White House’s Section 232 proclamation imposes a 100% duty on listed patented pharmaceutical imports and associated ingredients, with September 29 applicability for companies outside Annex III, alongside important exemptions and company-specific tariff treatment. The channel that dominates drug distribution is now navigating a new import-cost variable precisely where branded and specialty medicines matter most.

The tariff’s logic runs on global sourcing, and the response is already under way. GlobalData reports that Indian pharmaceutical companies are diversifying into Europe, emerging markets, and specialty segments ahead of threatened generic-drug tariffs. The exposure is large: according to the Indian Pharmaceutical Alliance, nearly half of all U.S. generic prescriptions are filled by Indian manufacturers, and ING estimates India supplies about 20% of the world’s generic medicines. GlobalData’s analyst cautions against reading it as a retreat — it is less about India pivoting away from the U.S. than about giving manufacturers more options, helped by new trade deals such as the UK–India agreement that took effect in July 2026. For distributors and pharmacies that rely on Indian-made generics, the signal is timing: even before tariffs begin, sourcing and market decisions are being made now.

Europe is pushing in a different direction from both the consolidated U.S. channel and India’s diversification: toward shared, cross-border digital infrastructure. Under the European Health Data Space, which entered into force in March 2025, the MyHealth@EU network already enables participating countries to exchange ePrescriptions and patient summaries. Key EU-wide cross-border functionality is expected by March 2029. A report commissioned by Redcare Pharmacy argues that this infrastructure could also help with medicine shortages, finding that shortages are often a distribution problem rather than an availability problem and proposing that authorised online pharmacies connected to MyHealth@EU could securely route available medicines to patients who need them. The finding is commissioned research, conducted by Erasmus University Rotterdam’s Institute for Medical Technology Assessment and Health Connect Partners. It is a pointed contrast with the U.S. model: Europe is building shared digital plumbing, and the open question is whether it can move medicines to where they are short.